Cutaneous Eruptions in the Course of COVID-19 Among Geriatric Patients in a Nursing Home in Poland

References

• Gorbalenya AE, Baker SC, Baric RS, et al. Severe acute respiratory syndrome-related coronavirus: the species and its viruses – a statement of the coronavirus study group. Microbiology. 2020. doi:10.1101/2020.02.07.937862
   Google Scholar
• World Health Organization. Coronavirus (COVID-19) Dashboard. Available from: https://covid19.who.int. Accessed February 26, 2022.
   Google Scholar
• AlSamman M, Caggiula A, Ganguli S, Misak M, Pourmand A. Non-respiratory presentations of COVID-19, a clinical review. Am J Emerg Med. 2020;38(11):2444–2454. doi:10.1016/j.ajem.2020.09.054
   PubMed Web of Science ®Google Scholar
• Singh H, Kaur H, Singh K, Sen CK. Cutaneous manifestations of COVID-19: a systematic review. Adv Wound Care. 2021;10(2):51–80. doi:10.1089/wound.2020.1309
   PubMed Web of Science ®Google Scholar
• Criado PR, Abdalla BMZ, de Assis IC, van Blarcum de Graaff Mello C, Caputo GC, Vieira IC. Are the cutaneous manifestations during or due to SARS-CoV-2 infection/COVID-19 frequent or not? Revision of possible pathophysiologic mechanisms. Inflamm Res. 2020;69(8):745–756. doi:10.1007/s00011-020-01370-w
   PubMed Web of Science ®Google Scholar
• Galván Casas C, Català A, Carretero Hernández G, et al. Classification of the cutaneous manifestations of COVID ‐19: a rapid prospective nationwide consensus study in Spain with 375 cases. Br J Dermatol. 2020;183(1):71–77. doi:10.1111/bjd.19163
   PubMed Web of Science ®Google Scholar
• Mawhirt SL, Frankel D, Diaz AM. Cutaneous manifestations in adult patients with COVID-19 and dermatologic conditions related to the COVID-19 pandemic in health care workers. Curr Allergy Asthma Rep. 2020;20(12):75. doi:10.1007/s11882-020-00974-w
   PubMed Web of Science ®Google Scholar
• Recalcati S. Cutaneous manifestations in COVID‐19: a first perspective. J Eur Acad Dermatol Venereol. 2020;34(5). doi:10.1111/jdv.16387
   Web of Science ®Google Scholar
• Jamshidi P, Hajikhani B, Mirsaeidi M, Vahidnezhad H, Dadashi M, Nasiri MJ. Skin manifestations in COVID-19 patients: are they indicators for disease severity? A systematic review. Front Med. 2021;8:634208. doi:10.3389/fmed.2021.634208
   Web of Science ®Google Scholar
• Perna A, Passiatore M, Massaro A, et al. Skin manifestations in COVID‐19 patients, state of the art. A systematic review. Int J Dermatol. 2021;60(5):547–553. doi:10.1111/ijd.15414
   PubMed Web of Science ®Google Scholar
• Zhao Q, Fang X, Pang Z, Zhang B, Liu H, Zhang F. COVID‐19 and cutaneous manifestations: a systematic review. J Eur Acad Dermatol Venereol. 2020;34(11):2505–2510. doi:10.1111/jdv.16778
   PubMed Web of Science ®Google Scholar
• Guan W, Ni Z, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–1720. doi:10.1056/NEJMoa2002032
   PubMed Web of Science ®Google Scholar
• Freeman EE, McMahon DE, Lipoff JB, et al. The spectrum of COVID-19–associated dermatologic manifestations: an international registry of 716 patients from 31 countries. J Am Acad Dermatol. 2020;83(4):1118–1129. doi:10.1016/j.jaad.2020.06.1016
   PubMed Web of Science ®Google Scholar
• Jindal R, Chauhan P. Cutaneous manifestations of coronavirus disease 2019 in 458 confirmed cases: a systematic review. J Family Med Prim Care. 2020;9(9):4563. doi:10.4103/jfmpc.jfmpc_872_20
   PubMedGoogle Scholar
• Muhammad A, Iftikhar N, Mashhood A, et al. Dermatological manifestations of COVID-19 in patients reporting to a tertiary care hospital in Rawalpindi, Pakistan. Cureus. 2021. doi:10.7759/cureus.18973
   Web of Science ®Google Scholar
• De Giorgi V, Recalcati S, Jia Z, et al. Cutaneous manifestations related to coronavirus disease 2019 (COVID-19): a prospective study from China and Italy. J Am Acad Dermatol. 2020;83(2):674–675. doi:10.1016/j.jaad.2020.05.073
   PubMed Web of Science ®Google Scholar
• Marzano AV, Cassano N, Genovese G, Moltrasio C, Vena GA. Cutaneous manifestations in patients with COVID‐19: a preliminary review of an emerging issue. Br J Dermatol. 2020;183(3):431–442. doi:10.1111/bjd.19264
   PubMed Web of Science ®Google Scholar
• Fernandez‐Nieto D, Ortega‐Quijano D, Jimenez‐Cauhe J, et al. Clinical and histological characterization of vesicular COVID‐19 rashes: a prospective study in a tertiary care hospital. Clin Exp Dermatol. 2020;45(7):872–875. doi:10.1111/ced.14277
   PubMed Web of Science ®Google Scholar
• Dursun R, Temiz SA. The clinics of HHV ‐6 infection in COVID ‐19 pandemic: pityriasis rosea and Kawasaki disease. Dermatol Ther. 2020;33:4. doi:10.1111/dth.13730
   Web of Science ®Google Scholar
• Drago F, Ciccarese G, Rebora A, Parodi A. Human herpesvirus‐6, ‐7, and Epstein‐Barr virus reactivation in pityriasis rosea during COVID‐19. J Med Virol. 2021;93(4):1850–1851. doi:10.1002/jmv.26549
   PubMed Web of Science ®Google Scholar
• Genovese G, Moltrasio C, Berti E, Marzano AV. Skin manifestations associated with COVID-19: current knowledge and future perspectives. Dermatology. 2021;237(1):1–12. doi:10.1159/000512932
   PubMed Web of Science ®Google Scholar
• Tamai M, Maekawa A, Goto N, et al. Three cases of COVID‐19 patients presenting with erythema. J Dermatol. 2020;47(10):1175–1178. doi:10.1111/1346-8138.15532
   PubMed Web of Science ®Google Scholar
• Tatu AL, Baroiu L, Fotea S, et al. A working hypothesis on vesicular lesions related to COVID-19 infection, koebner phenomena type V, and a short review of related data. Clin Cosmet Investig Dermatol. 2021;14:419–423. doi:10.2147/CCID.S307846
   PubMed Web of Science ®Google Scholar
• De Lucia M, Potestio L, Costanzo L, Fabbrocini G, Gallo L. Scabies outbreak during COVID‐19: an Italian experience. Int J Dermatol. 2021;60(10):1307–1308. doi:10.1111/ijd.15809
   PubMed Web of Science ®Google Scholar
• Veraldi S, Romagnuolo M, Benzecry V. Pityriasis rosea‐like eruption revealing COVID‐19. Australas J Dermatol. 2021;62:2. doi:10.1111/ajd.13504
   Web of Science ®Google Scholar
• Sachdeva M, Gianotti R, Shah M, et al. Cutaneous manifestations of COVID-19: report of three cases and a review of literature. J Dermatol Sci. 2020;98(2):75–81. doi:10.1016/j.jdermsci.2020.04.011
   PubMed Web of Science ®Google Scholar
• Broccolo F, Drago F, Careddu AM, et al. Additional evidence that pityriasis rosea is associated with reactivation of human herpesvirus-6 and −7. J Invest Dermatol. 2005;124(6):1234–1240. doi:10.1111/j.0022-202X.2005.23719.x
   PubMed Web of Science ®Google Scholar
• Birlutiu V, Birlutiu RM, Iancu GM. Pityriasis rosea Gibert triggered by SARS-CoV-2 infection: a case report. Medicine. 2021;100(14):e25352. doi:10.1097/MD.0000000000025352
   PubMed Web of Science ®Google Scholar
• Ehsani AH, Nasimi M, Bigdelo Z. Pityriasis rosea as a cutaneous manifestation of COVID-19 infection. J Eur Acad Dermatol Venereol. 2020;34(9):e436–e437. doi:10.1111/jdv.16579
   PubMed Web of Science ®Google Scholar
• Martín Enguix D, Salazar Nievas M, Martín Romero DT. Erupción tipo pitiriasis rosada de Gibert en una paciente asintomática con positividad para COVID-19. Medicina Clínica. 2020;155(6):273. doi:10.1016/j.medcli.2020.05.024
   PubMed Web of Science ®Google Scholar
• Merhy R, Sarkis AS, Stephan F. Pityriasis rosea as a leading manifestation of COVID‐19 infection. J Eur Acad Dermatol Venereol. 2021;35:4. doi:10.1111/jdv.17052
   Web of Science ®Google Scholar
• Johansen M, Chisolm SS, Aspey LD, Brahmbhatt M. Pityriasis rosea in otherwise asymptomatic confirmed COVID-19–positive patients: a report of 2 cases. JAAD Case Rep. 2021;7:93–94. doi:10.1016/j.jdcr.2020.10.035
   PubMedGoogle Scholar
• Yazdanpanah N, Rezaei N. Autoimmune complications of COVID-19. J Med Virol. 2022;94(1):54–62. PMID: 34427929; PMCID: PMC8661629. doi:10.1002/jmv.27292
   PubMed Web of Science ®Google Scholar
• Chacón Acevedo KR, Barrero Garzón LI, Rincón Ramírez KL, et al. Toxicodermia en paciente con COVID-19. Reporte de caso. Case Rep. 2021;7(1):74–80. doi:10.15446/cr.v7n1.88223
   Google Scholar
• Tatu AL, Elisei AM, Chioncel V, Miulescu M, Nwabudike LC. Immunologic adverse reactions of β-blockers and the skin. Exp Ther Med. 2019;18(2):955–959. doi:10.3892/etm.2019.7504
   PubMed Web of Science ®Google Scholar
• Ozaras R, Berk A, Ucar DH, Duman H, Kaya F, Mutlu H. Covid‐19 and exacerbation of psoriasis. Dermatol Ther. 2020;33:4. doi:10.1111/dth.13632
   Web of Science ®Google Scholar
• Ö K, Metin A. Dermatological diseases presented before COVID ‐19: are patients with psoriasis and superficial fungal infections more vulnerable to the COVID ‐19? Dermatol Ther. 2020;33(4). doi:10.1111/dth.13509
   Web of Science ®Google Scholar
• Mathieu RJ, Cobb CBC, Telang GH, Firoz EF. New-onset pustular psoriasis in the setting of severe acute respiratory syndrome coronavirus 2 infection causing coronavirus disease 2019. JAAD Case Rep. 2020;6(12):1360–1362. doi:10.1016/j.jdcr.2020.10.013
   PubMedGoogle Scholar
• Patrick MT, Zhang H, Wasikowski R, et al. Associations between COVID-19 and skin conditions identified through epidemiology and genomic studies. J Allergy Clin Immunol. 2021;147(3):857–869.e7. doi:10.1016/j.jaci.2021.01.006
   PubMed Web of Science ®Google Scholar
• Marasca C, Ruggiero A, Napolitano M, Fabbrocini G, Megna M. May COVID-19 outbreaks lead to a worsening of skin chronic inflammatory conditions? Med Hypotheses. 2020;143:109853. doi:10.1016/j.mehy.2020.109853
   PubMed Web of Science ®Google Scholar
• Gambichler T, Boms S, Susok L, et al. Cutaneous findings following COVID‐19 vaccination: review of world literature and own experience. Acad Dermatol Venereol. 2022;36(2):172–180. doi:10.1111/jdv.17744
   PubMed Web of Science ®Google Scholar
• Capoferri G, Daikeler T, Mühleisen B, Trendelenburg M, Müller S. Cutaneous leukocytoclastic vasculitis secondary to COVID-19 infection leading to extensive skin necrosis. Clin Dermatol. 2022;S0738081X22000281. doi:10.1016/j.clindermatol.2022.02.013
   Web of Science ®Google Scholar
• Santa Cruz A, Mendes-Frias A, Oliveira AI, et al. Interleukin-6 is a biomarker for the development of fatal severe acute respiratory syndrome coronavirus 2 pneumonia. Front Immunol. 2021;12:613422. doi:10.3389/fimmu.2021.613422
   PubMed Web of Science ®Google Scholar
• Villani A, Megna M, Scalvenzi M, Fabbrocini G, Ruggiero A. Teledermatology and chronic skin diseases: real life experience in a Southern Italian Dermatologic Centre. Dermatol Ther. 2020;33:6. doi:10.1111/dth.13839
   Web of Science ®Google Scholar
• Marasca C, Ruggiero A, Fontanella G, Ferrillo M, Fabbrocini G, Villani A. Telemedicine and support groups could be used to improve adherence to treatment and health‐related quality of life in patients affected by inflammatory skin conditions during the COVID‐19 pandemic. Clin Exp Dermatol. 2020;45(6):749. doi:10.1111/ced.14245
   PubMed Web of Science ®Google Scholar
• Marasca C, De Rosa A, Fabbrocini G, et al. Psychological teleconsultations in patients suffering from chronic skin diseases during the COVID-19 era: a service to improve patients’ quality of life. J Dermatolog Treat. 2022;33(3):1736–1737. doi:10.1080/09546634.2020.1809625
   PubMed Web of Science ®Google Scholar